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Abstract
The physical interaction of antithyroid drug, propylthiouracil was studied with 
bovine and human serum albumins through UV absorption and fluorescence 
spectroscopic techniques. The obtained values of the quenching constants 
were calculated by the Stern-Volmer equation are in the order of 1012 Lmol-1 s-1 
indicating that both serum albumins were quenched by the drug in a static manner. 
The binding constants of the drug interaction with both HSA and BSA proteins 
are found to be relatively weak and are in the order of 103 M-1. The tryptophan 
residues of HSA and BSA are most perturbed by the binding process which was 
authenticated by the fluorescence spectra of both proteins in the presence of 
propylthiouracil. The importance behind this study is to clarify the mechanism of 
the interaction between propylthiouracil with HSA and BSA, as well as providing 
additional values in order to study drug-protein interaction which may facilitate 
the study of drug metabolism and transportation.
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Introduction
One of the common diseases of this age is Graves' disease (GD), 
GD is an autoimmune thyroid disorder and it is one of the main 
causes of hyperthyroidism in areas with Iodine abundance, 
typically affects women than men and usually characterized by 
thyroid poisoning [1,2]. GD reported 20-30 cases per 100,000 
people each year, with 3% of women and 0.5% of men acquiring 
GD during their lifetime [3]. The antithyroid drug (ATD), 
structure provided in Figure 1 [4], It is exclusively prescribed to 
control hyperthyroidism in GD that inhibits the function of an 
enzyme to stimulate the synthesis of thyroid hormones [5-8]. 
ATDs obstructs the iodination of tyrosyl residues in thyroglobulin 
catalyzed by thyroid peroxidase, thereby arresting the production 
of thyroid hormones [9-11]. PTU is usually used only when 
methimazole, surgery, and radioactive iodine is not possible, as 
recommended for pregnant women [12-16].
Serum Albumin 
A drug binding to plasma proteins plays the major factor on 
the distribution, metabolism, pharmacological. Under different 
physiological and pathological conditions plasma proteins can 
be reduced, and severely restricted drugs can have a risk of 
enhanced activity and unwanted side effects [17]. Serum albumin 
is responsible for maintaining oncotic pressure in human plasma. 
Human Serum Albumin (HSA), its secondary structure presented 
in the top part of Figure 2 [18], is a single monomeric polypeptide 
of 585 amino acidic residues, it is a major protein component of 
human plasma with a typical concentration of 0.6 mM in the 
bloodstream [19] contributing significantly to the colloidal oncotic 
pressure and antioxidative capacity of human serum. X-ray 
crystallographic studies showed that HSA is composed of three 
homologous domains (I-III), each domain is further divided into 
subdomain A and B [20]. HSA has the possibility and the ability 
to bind in a non-covalent mode with a wide range of chemically 
different endogenous and exogenous ligands. The therapeutic 
efficiency of the ligands depends on their ability to bind to serum 
albumin and the mechanism involved in the binding. HSA- ligand 
complexes as provided by crystallographic studies have shown 
that drug-like compounds mainly interacts with one of two high-
affinity binding sites on the protein subdomains IIA and IIIA, 
Propylthiouracil (6-propyl-2-thiouracil) (PTU), its chemical 
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which make it potential for different drugs delivery [21]. These 
binding sites empower the HSA with an exceptional ability in 
binding various ligands which adds to its biological importance in 
delivering a number of drugs in the blood system to their targeting 
organs/tissues within the human body [22,23]. The intrinsic 
property of HSA that it contains a single tryptophan residue 
(Trp 214) in domain IIA and its fluorescence is highly sensitive to 
the ligands bounded nearby, therefore, this property is used as 
a probe to elucidate the binding properties of drugs with HSA. 
The fact that HSA possesses multiple binding sites for a number 
of ligands with a moderate binding affinity (104-106) suggests a 
high degree of flexibility of HSA [24-26], according to the recent 
biophysical studies, this flexibility is due to that HSA have the 
fastest hydrogen exchange rate in aqueous solution [27]. One 
of the most sequences related to HSA is Bovine Serum Albumin 
(BSA), the secondary structure provided in the bottom part of 
Figure 2 [28]. The similarity between HSA and BSA is 76% in terms 
of identity and 88% in terms of amino acid sequences [29]. It is 
likely that depending on the content of fatty acids, pH, and ionic 
forces these three domains denature regardless of each other or 
can unite. The primary structure of BSA was elucidated by Brown 
in 1975, BSA contains the 607 amino acid residue, twenty-one of 
which is tyrosine (Tyr) residues and two of which are tryptophan 
(Trp) residues located at positions 134 and 213, respectively 
which cause BSA to have intrinsic fluorescence [30,31]. 
The reversible drug-protein complex formation has attained a 
great concern in pharmacokinetics because this formation made 
through weaker chemical bonds, for example, hydrogen bonds or 
Van der Waals forces [32,33].
Different studies and experiments reported in the literature 
were used to clarify the interaction of serum albumin with small 
molecules, drugs and toxic chemicals using the fluorescence 
method [34,35]. But there has been no work study the interaction 
of propylthiouracil with protein albumin. Thus, the present work 
aimed to obtain a detail and insightful information of HSA and BSA 
binding with propylthiouracil using UV-visible and fluorescence 
spectroscopy. Fluorescence spectroscopy is a powerful 
technique in providing structural changes information due to 
quenching upon intermolecular forces. Thus, the fluorescence 
technique provides data to calculate binding constants and 
binding sites. The study of the interaction of PTU with HSA 
and BSA may facilitate the mechanism of the transportation of 
hyperthyroid drug and to understand the binding type of drug-
protein interaction in addition to the precise knowledge of drug-
biomolecular interactions which is crucial for a rational design of 
pharmaceuticals.
In this work, we study the interactions of propylthiouracil with 
human and bovine serum albumins applying different supportive 
data including a binding parameter, quenching, and nature of 
binding. However, this data obtained from UV absorption and 
fluorescence spectroscopic techniques. The importance of this 
investigation lies in the well-recognized role of the two serum 
albumins as a drug transporter to target specified organs.
Materials and Samples Preparation
Propylthiouracil (170.2 g/mol), human and bovine serum 
albumins (66.5 kDa) in powder form were purchased from Sigma 
Aldrich chemical company and were used without any further 
purifications. HSA and BSA stock solutions were prepared and 
dissolved in phosphate buffer saline with pH of 7.4 to obtain a 
concentration of 80 mg/ml which corresponds to 1.2 mM. The 
final concentration of HAS and BSA in the HSA/BSA-PTU complex 
was 40 mg/ml equivalent to the molarity of 0.6 mM which is 
comparable to its concentration in the blood. The stock solution 
of PTU with a molarity of 2.6 mM was prepared by dissolving 
the drug in ethanol. PTU standard solutions were prepared by 
successive dilutions. The HSA/BSA-PTU complexes were prepared 
by mixing equal volumes of 1.2 mM HSA/BSA molarity and 
each of the standard PTU solutions. The final concentration of 
HSA and BSA were kept at (40 mg/ml) in all samples while the 
concentrations of propylthiouracil in the final HSA/BSA-PTU 
solutions were reduced to be as (0.5 mM, 0.7 mM, 0.9 mM, 1.1 
mM, and 1.3 mM).
Instruments
UV-VIS absorption spectra
A spectrophotometer is a powerful technique which is used to 
measure the absorption spectrum of the samples in the range 
between 220-750 nm, with high accuracy and reproducibility. 
The data was collected using 5µL samples using NanoDrop ND-
 
Chemical structure of Propylthiouracil.Figure 1
 
(a) (b) 
Secondary structure of (a) HAS; (b) BSA.Figure 2
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1000 Spectrophotometer for the free HSA/BSA (0.6 mM) and 
for the HSA/BSA-PTU complexes ‘solutions with the following 
concentrations (0.5, 0.7, 0.9, 1.1 and 1.3) mM. UV measurements 
were repeated for all the samples and no significant differences 
were observed. The UV-absorption spectra for both complexes 
HSA-PTU and BSA-PTU are obtained at the wavelength of 280 nm. 
Fluorescence
Fluorescence data were obtained by a NanoDrop ND-3300 Fluoro-
spectrophotometer for the following complexes concentration 
(0.5, 0.7, 0.9, 1.1 and 1.3) mM at 25°C. The excitation source 
comes from one of three solid-state Light Emitting Diodes 
(LEDs) which have options that include: UV LED with maximum 
excitation 365 nm, Blue LED with excitation 470 nm, and white 
LED from 500 to 650 nm excitation. A 2048-element CCD array 
detector covering 400-750 nm, is connected by an optical fiber to 
the optical measurement surface. The excitation is done for both 
complexes HSA-PTU and BSA-PTU at the wavelength of 390 nm 
and the maximum emission wavelength is at 440 nm.
Results and Discussions
UV-VIS absorption spectra
Ultraviolet and visible spectrometers have been used for many 
years and have become one of the important analytical instruments 
in modern laboratories because of its simplicity, versatility, 
speed, accuracy, and cost-effectiveness [36]. This experimental 
technique was used to calculate the binding constants for several 
drug-protein complexes [37]. The UV absorption data of HSA-PTU 
and BSA-PTU complexes were obtained and presented in Figure 
3. The figure shows a maximum absorption peak at a wavelength 
of 280 nm, the spectrums provide a direct relationship between 
the increase in peak intensity of the HSA-PTU (top) and BSA-
PTU (bottom) complexes and the concentration of the PTU. The 
increase in the intensity is due to the interaction between HSA/
BSA and PTU as monitored in buffered solution by scanning the 
wavelengths. As indicated in the figure, there is a clear absorption 
signal for free PTU.
as presented in Figure 4. When a fixed concentration of HSA 
or BSA was allowed to complex with different amounts of PTU, 
there is a linear increase in the UV absorbance of HSA or BSA. The 
binding constants for the HSA-PTU and BSA-PTU complexes were 
calculated using UV spectra according to published methods 
[22,38] with the assumption that there is one-to-one interaction 
between HSA/BSA and PTU in aqueous solution to establish 
chemical equilibrium as in the following equations. 
HSA+PTU ↔  HSA:DA                    (1)
BSA+PTU ↔  BSA:DA                    (2)
The corresponding formation/binding constants for both proteins 
are given by: 
K = [HSA: PTU]/[PTU] [HSA]                   (3)
K = [BSA: PTU]/[PTU] [BSA]                   (4)
Accordingly, the UV absorbance spectra were treated using linear 
double reciprocal plots based on the following equation.
 
 
UV absorbance spectra of HSA-PTU (top) and BSA-
PTU (bottom), with maximum absorbance at 280 
nm and temperature at 25°C. Free HSA and free BSA 
(40 mg/mL, 0.6 mM) and free HSA with different 
PTU concentrations (a= free HSA/BSA (0.6 mM), b-f 
correspond to HSA/BSA-PTU complexes with (0.5, 
0.7, 0.9, 1.1 and 1.3) mM PTU respectively.
Figure 3
The plot of 
0
1
(A - A )
 vs.   
 
1
L
 for free HSA and free BSA 
with different HSA/BSA-PTU complex concentrations.
Figure 4
From Eq. 5, the reciprocal plot of 1/(A-Ao) versus (1/L) is linear 
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Where Ao corresponds to the initial absorption of HSA or BSA at 
280 nm in the absence of ligand, A∞ is the final absorption of the 
HSA or BSA, and A is the recorded absorption at different PTU 
concentration (L). 
The binding constants (K) for both protein interactions with 
propylthiouracil were estimated from the ratio of the intercept 
to the slope found from Figure 4. It was found that both binding 
constant values are close to each other with KHSA-PTU equals to 
1.45 × 103 M-1 and KBSA-PTU found to be 1.14 × 10
3 M-1. The value 
for both binding constants is an indication of weak intermolecular 
force interaction between the HSA/BSA and PTU when compared 
to reported protein-drug interaction with a binding constant in 
the range of 104 and 106 M-1 [39]. The importance of the binding 
constant value stems from its valuable application in drug delivery 
and pharmacokinetics [23] therefore, absorbance measurements 
were constantly repeated and similar results were obtained 
consistently. 
Fluorescence emission spectroscopy
In order to study the reactivity of chemicals and biological 
systems; fluorescence technique is an effective and powerful 
tool because it allows nonintrusive measurements of substances 
in low concentration under physiological conditions. Since 
the amino acids tryptophan, tyrosine and phenylalanine are 
fluorescent in nature, thus contributing to the fluorescence of 
the protein in which they are present [40]. Among the two amino 
acid residues, Trp is highly fluorescent and sensitive to the micro-
environmental changes that might occur in its vicinity whereas 
phenylalanine does not get excited (for the most part) easily and 
has a low quantum yield. Owing to these reasons, Trp is usually 
used in quenching studies.
The effect of propylthiouracil on the fluorescence emission 
spectrum of HSA and BSA, excited at 390 nm are presented in 
Figure 5. The emission spectrum for the two complexes showed 
a maximum emission wavelength at 440 nm. The definition of 
fluorescence quenching is the reduction of the quantum yield 
of fluorescence from a fluorophore. When a fluorophore is 
substantially induced with quencher molecule by a variety of 
molecular interaction (i.e. excited state reactions, energy transfer, 
molecular rearrangements, and ground-state complex formation) 
quenching of fluorescence is evident [41]. The quenching took 
place in a concentration-dependent manner; as the concentration 
of PTU increases result in a decrease in HSA and BSA fluorescence 
intensity.
The HSA and BSA fluorescences are decreased upon increasing 
concentrations of PTU, which indicates that the PTU is interacting 
with HSA and BSA in the surrounding of the fluorescent residues 
Trp214 (HSA), Trp213 and Trp134 (BSA). This interaction of PTU 
affects the two proteins fluorescence upon binding to PTU due to 
the quenching ability of tryptophan residues upon colliding with 
PTU. 
Fluorescence quenching can be processed through different 
mechanisms, typically classified as dynamic quenching and static 
quenching. In order to ensure the quenching mechanism, the 
fluorescence data between quenching efficiency (F0/F) and the 
concentration of quencher (L) for the complete static or dynamic 
quenching mode should satisfy the following Stern-Volmer 
equation [42].
[ ] [ ]0 01 1sv q
F K L k L
F
τ= + = +                     (5)
where F0 and F are the fluorescence intensity of fluorophore in 
the absence and in the presence of quencher, respectively, (L) 
is the concentration of quencher (PTU), Ksv in M
-1 is the Stern-
Volmer constant corresponding to the slope of the plot for F0/F 
versus (L) as shown in Figure 5, k
q
 is the quenching rate constant 
for biomolecular quenching in M-1s-1, and τ0 is the average 
fluorescence lifetime of fluorophore without quencher evaluated 
at about 10-8 [40].
As seen in Figure 6, the curves are linear which suggests the 
existence of a single type of quenching (dynamic or static) and/
or a single binding site for both complexes., the fluorescence 
quenching constant values for HSA-PTU and BSA-PTU are 
Fluorescence emission spectra of HSA-PTU (top) and 
BSA-PTU (bottom), with maximum absorbance at 
340 nm and temperature at 25°C. Free HSA and free 
BSA (40 mg/mL, 0.6 mM) and free HSA with different 
PTU concentrations (a= free HSA/BSA (0.6 mM), b-f 
correspond to HSA/BSA-PTU complexes with (0.5, 
0.7, 0.9, 1.1 and 1.3) mM PTU respectively.
Figure 5
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calculated by applying Eq. 5 and are equal to (3.47 × 104, 3.15 
× 104) Lmol-1 respectively. The obtained values of k
q
 (3.47 × 1012, 
3.15 × 1012) Lmol-1s-1 for HSA-PTU and BSA-PTU respectively, 
the attained values of k
q
 were more than the limiting diffusion 
constant of the biomolecule (2 × 1010 L mol-1s-1) [43]. Thus, it is 
proposed that the complex formation takes a major role rather 
than a dynamic collision for the interaction of HSA/BSA-PTU. 
In addition, this evidence indicated that a static quenching was 
dominant in the system [44].
One of the most frequently used equations used to calculate the 
binding constant of the drug-protein interaction is the modified 
Stern-Volmer equation [45]. 
( )0 0 0
1 1 1
F F F K L F
= +
−
                      (6)
In order to calculate the binding constant K of HSA-PTU and BSA-
PTU complexes, a plot of the reciprocal of the difference between 
the unquenched fluorescence and the quenched fluorescence 
0
1
F F
 
 − 
 vs the reciprocal concentration pf PTU 1
L
 
 
 
 as shown in 
Figure 7. The presented curves are linear and have a slope of 
0
1
F K
and intercept 
0
1
F
 according to Eq. 5.
The obtained values of K were found to be (1.29 × 103 M-1, 0.98 
× 103 M-1), which are very close to the values obtained by UV 
spectroscopic technique and supports the effective role of static 
quenching.
The obtained binding constant values illustrated that there was a 
weak binding force between PTU and the two serum albumins and 
this is due to the limited number of binding sites for endogenous 
and exogenous ligands that has serum albumin. Because these 
ligands have binding constants ranging from 104 to 108 (significant 
interaction) and reversibly bound [46].
Conclusion
To conclude, the complex interaction between PTU with 
HSA and BSA has been investigated by using UV absorption 
and fluorescence spectroscopic techniques in a steady-state 
manner. The values of the binding constants (~103 M-1) for both 
complexations obtained from both techniques were found to 
be relatively week. The quenching constant values for both 
interactions were found to be in the order of 1012 L mol-1s-1 which 
justifies that the intrinsic fluorescence of both HSA and BSA were 
quenched by PTU in a static mode, and the linear plot of Stern-
Volmer equation supports the idea of static quenching. 
The results obtained in this work facilitate the understanding of 
the HSA and BSA interaction with PTU. The biological significance 
of this investigation lies in the well-recognized role of the two 
serum albumins as a drug transporter to target specified organs 
in such a way that the target organ could be cured therefore it 
is very important to understand the various types of molecular 
interactions of HSA and BSA with drugs which will be essential in 
the drug delivery and in promotion alternative foundations for 
new pathways of drug delivery.
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The Stern-Volmer plot for HSA/BSA-PTU complexes.Figure 6
Modified Stern-Volmer plot for HSA/BSA-PTU 
complexes.
Figure 7
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